The mRNA expression levels of NT5C2 were associated with adverse clinical outcome in adult AML patients treated with ara-C [22], and, when combined with expression levels of DCK, negatively correlated with accumulation of ara-CTP in primary paediatric AML cells, and ara-C sensitivity in AML cell lines [23,24,25]. This evidence concerns the gene DCK and acute myeloid leukemia.